Current prostate cancer: 20 Years later

BJU International

Volumn 100, Issue SUPPL. 2, 2007, Pages 11-14

  Marberger, Michael ^a  

^a UNIVERSITY OF VIENNA   (Austria)

Author keywords

[No Author keywords available]

Indexed keywords

ANTIZYME; COLLAGEN; COLLAGEN TYPE XXIII; KI 67 ANTIGEN; PROSTATE SPECIFIC ANTIGEN; PROTEIN BCL 2; THYMOSIN; THYMOSIN BETA 15; UNCLASSIFIED DRUG;

ANTIGEN DETECTION; CANCER DIAGNOSIS; CANCER RADIOTHERAPY; CANCER REGISTRY; CANCER SURGERY; HUMAN; INCONTINENCE; MEDICAL LITERATURE; NOMOGRAM; NUCLEAR MAGNETIC RESONANCE IMAGING; PRIORITY JOURNAL; PROSTATE CANCER; REVIEW; SEXUAL DYSFUNCTION; SEXUAL FUNCTION; TRANSRECTAL ULTRASONOGRAPHY; UNITED STATES;

HUMANS; INCIDENCE; MAGNETIC RESONANCE IMAGING; MALE; PROSTATE-SPECIFIC ANTIGEN; PROSTATIC NEOPLASMS; RISK FACTORS; TUMOR MARKERS, BIOLOGICAL;

EID: 34250802157     PISSN: 14644096     EISSN: 1464410X     Source Type: Journal    
DOI: 10.1111/j.1464-410X.2007.06945.x     Document Type: Review

References (27)

1. Killian CS, Yang N, Emrich LJ et al. Prognostic importance of prostate-specific antigen for monitoring patients with stages B2 to D1 prostate cancer. Cancer Res 1985 45 : 886 91
2. Albertsen PC, Hanley JA, Gleason DF, Barry MJ. Competing risk analysis of men aged 55-74 years at diagnosis managed conservatively for clinically localized prostate cancer. JAMA 1998 280 : 975 80
3. Bill-Axelson A, Holmberg L, Ruutu M et al. Radical prostatectomy versus watchful waiting in early prostate cancer. N Engl J Med 2005 352 : 1977 84
4. Cooperberg MR, Broering JM, Latini DM, Litwin MS, Wallace KL, Carroll PR. Patterns of practice in the United States: insights from CaPSURE on prostate cancer management. Curr Urol Rep 2004 5 : 166 72
5. Cooperberg MR, Lubeck DP, Mehta SS, Carroll PR CaPSURE. Time trends in clinical risk stratification for prostate cancer: implications for outcomes (data from CaPSURE). J Urol 2003 170 : S21 7
6. Statistik Austria. Jahrbuch der Gesundheitsstatistik 2005. Vienna : Verlag Österreich, 2006. Available at: http://www.statistik.at. Accessed April 2007
7. Davidson P, Gabbay J. Should Mass Screening for Prostate Cancer Be Introduced at the National Level? Health Evidence Network Report. Copenhagen : WHO Regional Office for Europe. Available at: http://www.euro.who.int/Document/ E82958.pdf. Accessed April 2007
8. Hernández J, Thompson IM. Prostate-specific antigen: a review of the validation of the most commonly used cancer biomarker. Cancer 2004 101 : 894 904
9. Kobayashi T, Nishizawa K, Ogura K, Mitsumori K, Ide Y. Detection of prostate cancer in men with prostate-specific antigen levels of 2.0-4.0 ng/mL equivalent to that in men with 4.1-10.0 ng/mL in a Japanese population. Urology 2004 63 : 727 31
10. Sokoloff MH, Yang XJ, Fumo M, Mhoon D, Brendler CB. Characterizing prostatic adenocarcinomas in men with a serum prostate specific antigen level of <4.0 ng/mL. BJU Int 2004 93 : 499 502
11. Horninger W, Berger AP, Rogatsch H et al. Characteristics of prostate cancers detected at low PSA levels. Prostate 2004 58 : 232 7
12. Nishio R, Furuya Y, Nagakawa O, Fuse H. Metastatic prostate cancer with normal level of serum prostate-specific antigen. Int Urol Nephrol 2003 35 : 189 92
13. Thompson IM, Pauler DK, Goodman PJ et al. Prevalence of prostate cancer among men with a prostate-specific antigen level < or = 4.0 ng per milliliter. N Engl J Med 2004 350 : 2239 46
14. Chatterjee SK, Zetter BR. Cancer biomarkers: knowing the present and predicting the future. Future Oncol 2005 1 : 37 50
15. Bostwick DG, Gould VE, Qian J, Susani M, Marberger M. Prostate cancer detected by uPM3: radical prostatectomy findings. Mod Pathol 2006 19 : 630 3
16. Tinzl M, Marberger M, Horvath S, Chypre C. DD3PCA3 RNA analysis in urine - a new perspective for detecting prostate cancer. Eur Urol 2004 46 : 182 7
17. Fütterer JJ, Engelbrecht MR, Huisman HJ et al. Staging prostate cancer with dynamic contrast-enhanced endorectal MR imaging prior to radical prostatectomy: experienced versus less experienced readers. Radiology 2005 237 : 541 9
18. Di Blasio CJ, Rhee AC, Cho D, Scardino PT, Kattan MW. Predicting clinical end points: treatment nomograms in prostate cancer. Semin Oncol 2003 30 : 567 86
19. Wang L, Hricak H, Kattan MW et al. Prediction of seminal vesicle invasion in prostate cancer: incremental value of adding endorectal MR imaging to the Kattan nomogram. Radiology 2007 242 : 182 8
20. Roach M 3rd, Weinberg V, Nash M, Sandler HM, McLaughlin PW, Kattan MW. Defining high risk prostate cancer with risk groups and nomograms: implications for designing clinical trials. J Urol 2006 176 (Suppl. S16 20
21. Chun FK, Karakiewicz PI, Briganti A et al. Prostate cancer nomograms: an update. Eur Urol 2006 50 : 914 26
22. Litwin MS, Flanders SC, Pasta DJ, Stoddard ML, Lubeck DP, Henning JM. Sexual function and bother after radical prostatectomy or radiation for prostate cancer: multivariate quality-of-life analysis from CaPSURE. Urology 1999 54 : 503 8
23. Kundu SD, Roehl KA, Eggener SE, Antenor JAV, Han M, Catalona WJ. Potency, continence and complications in 3477 consecutive radical retropubic prostatectomies. J Urol 2004 172 : 2227 31
24. Klingler HC, Marberger M. Incontinence after radical prostatectomy: surgical treatment options. Curr Opin Urol 2006 16 : 60 4
25. Clark JA, Wray NP, Ashton CM. Living with treatment decisions: regrets and quality of life among men treated for metastatic prostate cancer. J Clin Oncol 2001 19 : 72 80
26. Parker C. Active surveillance: towards a new paradigm in the management of early prostate cancer. Lancet Oncol 2004 5 : 101 6
27. Pomerantz M, Kantoff P. Advances in the treatment of prostate cancer. Annu Rev Med 2007 58 : 205 20